Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
Top Cited Papers
- 1 May 2019
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 53 (5), 1900164
- https://doi.org/10.1183/13993003.00164-2019
Abstract
Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic and biological information in order to optimise the therapeutic benefit relative to the possibility of sideeffects for each individual. Recent clinical trials have shown that higher blood eosinophil counts are associated with a greater efficacy of inhaled corticosteroids (ICSs) in chronic obstructive pulmonary disease (COPD) patients. Blood eosinophil counts are a biomarker with potential to be used in clinical practice, to help target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 pharmacological treatment algorithms, based on the ABCD assessment, can be applied relatively easily to treatment-naive individuals at initial presentation. However, their use is more problematic during follow-up in patients who are already on maintenance treatment. There is a need for a different system to guide COPD pharmacological management during follow-up. Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations. The new evidence regarding blood eosinophils and inhaled treatments, and the need to distinguish between initial and follow-up pharmacological management, led to changes in the GOLD pharmacological treatment recommendations. This article explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.This publication has 49 references indexed in Scilit:
- Eosinophilic inflammation in COPD: prevalence and clinical characteristicsEuropean Respiratory Journal, 2014
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEuropean Respiratory Journal, 2013
- Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Repeatability of Inflammatory Parameters in Induced Sputum of COPD PatientsCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2007
- Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary diseaseThorax, 2005
- Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatabilityRespiratory Medicine, 2001
- Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2000
- Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPDEuropean Respiratory Journal, 2000